CPN2

Across TCGA pan-cancer cohorts, CPN2 mass-spec protein is linked to patient survival in 9 of 34 cancer types, making it a survival-associated CPN2 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CPN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CPN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where CPN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.209	0.740	<.001	46	view →
COAD	DFS	Median	II,III,IV	0.880	1.000	.020	24	view →
CCRCC	DFS	Median	All	0.917	0.701	.006	17	view →
OV	DFS	Median	All	0.900	0.672	.017	16	view →
GBM	DFS	Tertile	All	0.545	0.234	.008	10	view →
UCEC	DFS	Tertile	III,IV	0.409	1.000	.020	6	view →
LSCC	OS	Median	II,III,IV	0.887	1.000	.028	2	view →
PDAC	OS	Quartile	III,IV	0.362	1.000	.040	2	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

CPN2–LUAD (OS)

Open the LUAD breakdown →